Загрузка...
New emerging targets in cancer immunotherapy: the role of LAG3
The success of immunotherapy in many disease entities is limited to a specific subpopulation of patients. To overcome this problem, dual blockade treatments mainly against cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and programmed cell death receptor (ligand) 1 (PD-(L)1) axis were developed....
Сохранить в:
| Опубликовано в: : | ESMO Open |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMJ Publishing Group
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6555869/ https://ncbi.nlm.nih.gov/pubmed/31231559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000482 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|